Author

S. M. Rainey

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:clinical cohort / trial· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Kohl· 1 shared A. M. Szemiel· 1 shared A. Taggart· 1 shared C. Davis· 1 shared D. Kovacs· 1 shared E. C. Thomson· 1 shared F. Marra· 1 shared J. T. Scott· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. Kohl

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

COVID-19: A need for new rather than repurposed antiviral drugs.

D. Kovacs, C. Davis, P. Cannon, M. McFarlane, S. M. Rainey, R. Pinto, M. E. Stewart, A. M. Szemiel, A. Taggart, A. Kohl, F. Marra, E. C. Thomson, J. T. Scott

This paper reviews 29 FDA-approved antiviral compounds for COVID-19 treatment, finds limited clinical efficacy of repurposed drugs, and highlights the need for novel antivirals.

bioRxiv · Mar 25, 2021 · PreprintMicrobiology